Harvard Bioscience Tops Q2 Revenue Views

Harvard Bioscience (NASDAQ:HBIO), a provider of specialized laboratory technologies for biomedical and life sciences research, released its financial results for the second quarter of fiscal 2025 on August 11, 2025. GAAP revenue came in ahead of analyst predictions at $20.5 million in Q2 2025, outpacing the $18.75 million GAAP consensus by $1.75 million. This top-line beat comes even as GAAP revenue dropped 11.3% year-over-year. Non-GAAP earnings per share (EPS) showed a smaller loss than anticipated, recorded at $(0.01) compared to the estimated $(0.025). Year over year, operating cash flow (GAAP) made a significant turnaround, swinging from a negative $0.8 million to a positive $2.8 million. However, gross margin (GAAP) narrowed to 56.4%. Overall revenue continues to trend downward, with GAAP revenue decreasing from $23.1 million in Q2 2024 to $20.5 million in Q2 2025. Some traction in new product segments but also highlighted persistent profitability and market headwinds. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Harvard Bioscience makes laboratory instruments and devices that support research in areas like drug discovery, therapy development, and preclinical testing. Its core products are used by universities, pharmaceutical firms, and contract research organizations to test new drugs, analyze cellular behavior, and monitor laboratory animals in both basic and advanced research. Product lines include implantable telemetry (wireless monitoring for lab animals), electroporation systems for bioproduction and therapy, and the MeshMEA system (microelectrode array platforms for organoid and cellular activity studies).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool